{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T11:50:56Z","timestamp":1771674656427,"version":"3.50.1"},"reference-count":15,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2007,9,6]],"date-time":"2007-09-06T00:00:00Z","timestamp":1189036800000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Skinmed"],"published-print":{"date-parts":[[2007,9]]},"abstract":"<jats:p> <jats:bold>\n            <jats:italic>Background.<\/jats:italic>\n          <\/jats:bold>\n          <jats:italic>Two large clinical trials have recently demonstrated the efficacy of a 40\u2010mg controlled\u2010release formulation of doxycycline in the treatment of rosacea, a dose well below the conventional level of 100 to 200 mg\/d. Since no formal dose\u2010response studies have been conducted, the authors analyzed phase 3 data to determine whether a dose\u2010efficacy relationship exists.<\/jats:italic> <\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Methods.<\/jats:italic>\n          <\/jats:bold>\n          <jats:italic>Standard parametric regression analyses were used to estimate the correlations between dose (mg\/kg body weight) and overall drug exposure (area under the curve [AUC]) in a phase 1 pharmacokinetic study and between dose and efficacy (mean change from baseline in total inflammatory lesion count at week 16) in 2 pooled phase 3 clinical efficacy studies. Additional regressions were run at each visit for the clinical efficacy studies to determine whether results differed across visits. A regression analysis was also performed in a subset of patients who showed a greater efficacy response.<\/jats:italic> <\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Results.<\/jats:italic>\n          <\/jats:bold>\n          <jats:italic>We found overall drug exposure (AUC) to have a highly significant correlation with dose (mg\/kg) (<\/jats:italic>r<jats:italic>=0.49;<\/jats:italic> P<jats:italic>=.006). In contrast, clinical efficacy did not correlate with dose at any of the visits at week 3 (<\/jats:italic>r<jats:italic>=0.01;<\/jats:italic> P<jats:italic>=.85), week 6 (<\/jats:italic>r<jats:italic>=0.04;<\/jats:italic> P<jats:italic>=.53), week 12 (<\/jats:italic>r<jats:italic>&lt;0.01;<\/jats:italic> P<jats:italic>=.98), and week 16 (<\/jats:italic>r<jats:italic>=0.03;<\/jats:italic> P<jats:italic>=.64) or among the subset of patients who showed greater clinical benefit.<\/jats:italic><\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Conclusions.<\/jats:italic>\n          <\/jats:bold>\n          <jats:italic>Higher mg\/kg doses led to higher plasma concentrations but did not lead to increased clinical efficacy. Anti\u2010inflammatory dose doxycycline (40\u2010mg controlled\u2010release formulation) conferred peak anti\u2010inflammatory efficacy in the treatment of rosacea.<\/jats:italic> <\/jats:p><jats:p> <jats:bold>\n            <jats:italic>(SKINmed. 2007;6:221\u2013226)<\/jats:italic>\n          <\/jats:bold> <\/jats:p>","DOI":"10.1111\/j.1540-9740.2007.06460.x","type":"journal-article","created":{"date-parts":[[2007,9,6]],"date-time":"2007-09-06T15:31:24Z","timestamp":1189092684000},"page":"221-226","source":"Crossref","is-referenced-by-count":15,"title":["Anti\u2010Inflammatory Dose Doxycycline (40 mg Controlled\u2010Release) Confers Maximum Anti\u2010Inflammatory Efficacy in Rosacea"],"prefix":"10.1111","volume":"6","author":[{"given":"Klaus","family":"Theobald","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Bradshaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Leyden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,9,6]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.11.021"},{"key":"e_1_2_7_3_2","unstructured":"Oracea [package insert]. Newtown PA:CollaGenex Pharmaceuticals Inc;2006."},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1902\/jop.2000.71.9.1472"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1902\/jop.2000.71.9.1465"},{"key":"e_1_2_7_6_2","unstructured":"WalkerC WebsterGA.Multicenter double\u2010blind randomized trial to evaluate long\u2010term anti\u2010inflammatory dose doxycycline (40 mg) therapy: results of the lack of effect on bacterial flora. Presented at:Fall Clinical Dermatology Conference;October 69 2006; Las Vegas NV."},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0765.1983.tb00388.x"},{"key":"e_1_2_7_8_2","first-page":"80","article-title":"Host modulation with tetracyclines and their chemically modified analogues","volume":"2","author":"Golub LM","year":"1992","journal-title":"Curr Opin Dent"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-051X.1995.tb00120.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.110901"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.618"},{"key":"e_1_2_7_12_2","first-page":"149","article-title":"Treatment of rosacea with doxycycline monohydrate","volume":"66","author":"Bikowski JB","year":"2000","journal-title":"Cutis"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp042829"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3597(01)90003-1"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1053\/sder.2001.27554"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1994.01690030091015"}],"container-title":["SKINmed: Dermatology for the Clinician"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1540-9740.2007.06460.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1540-9740.2007.06460.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T19:23:46Z","timestamp":1696965826000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1540-9740.2007.06460.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["10.1111\/j.1540-9740.2007.06460.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1540-9740.2007.06460.x","archive":["Portico"],"relation":{},"ISSN":["1540-9740","1751-7125"],"issn-type":[{"value":"1540-9740","type":"print"},{"value":"1751-7125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}